Neuralstem


Neuralstem, Inc. (CUR): Updated Phase II Trial Success in Major Depressive Disorder Takes the Street by Storm

Neuralstem (NASDAQ:CUR) stock is on fire after revealing a huge clinical win that has sent bulls storming the market today to buy into …

Company Update (NYSE MKT:CUR): Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market

Neuralstem, Inc. (NYSE MKT:CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous …

Company Update (NYSE MKT:CUR): Preclinical Data On Neuralstem, Inc.’s Genetically Modified HK532-IGF-1 Stem Cells In Alzheimer’s Disease

Neuralstem, Inc. (NYSE MKT:CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous …

Stock Update (NYSE MKT:CUR): Neuralstem, Inc. Reports First Quarter 2015 Financial Results And Provides Business and Clinical Update

Neuralstem, Inc. (NYSE MKT:CUR) a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous …

Stock Update (NYSE:CUR): Neuralstem Reports Fiscal 2014 Fourth Quarter Financial And Year-End Business Results

Neuralstem, Inc. (NYSE MKT: CUR) reported its financial results for the fourth quarter and year ended December 31, 2014.

Stock Update (NYSE MKT:CUR): Neuralstem Announces Topline Results Of Phase II ALS Trial

Neuralstem, Inc. (NYSE MKT: CUR) announced top line data from the Phase II trial of NSI-566 spinal cord-derived neural stem cells under development for …

Brean Capital Initiates Buy On Neuralstem, Inc., Sees 126% Upside For The Stock

In a research report issued this morning, Brean Capital analyst Jonathan Aschoff initiated coverage on shares of Neuralstem (NYSE:CUR) with a Buy rating and …

Neuralstem Shares Are Currently Fairly Valued, Says H.C. Wainwright

In a research report sent to investors today, H.C.

H.C. Wainwright Comments On Neuralstem Following Presentation At The Annual Symposium On ALS

In a research report issued today, H.C.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts